RxDoctor Payments Data

Thomas Bradley, MD

Hematology & Oncology · Monterey, CANPI 1902979644

Payments from drug & device makers

$8,190in general payments, 2019–2025

Across 385 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$990
  • Pfizer$538
  • Novartis$470
  • AstraZeneca$441
  • Eisai Inc.$346
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,04498%
  • Education$1462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,190 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$304,262
Medicare patients
608
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib24$349,745
PomalystPomalidomide12$282,147
KisqaliRibociclib Succinate15$263,371
Lenalidomide15$205,488
ImbruvicaIbrutinib12$184,812
EliquisApixaban151$134,496
XareltoRivaroxaban80$76,015
Deferasirox11$46,086
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$43,396
OxycontinOxycodone Hcl22$13,183
ProzacFluoxetine Hcl24$10,430
Celecoxib157$10,286
Breo ElliptaFluticasone/Vilanterol22$7,982
Repatha SureclickEvolocumab12$6,689
Exemestane15$4,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$30$349,74524 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$990$282,14712 claims
NovartisKisqali$470$263,37115 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$26$184,81212 claims
PfizerEliquis, Paxlovid$538$135,925163 claims
Johnson & JohnsonXarelto$1,304$76,01580 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$94$43,39613 claims
GSKBreo Ellipta$160$7,98222 claims
AbbVieSynthroid$132$1,52218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →